2. Zilberberg M.D., Shorr A.F., Micek S.T. et al. Epidemiology and outcomes of hospitalizations with complicated skin and skin-structure infections: implications of healthcare-associated infection risk factors. Infect. Control. Hosp. Epidemiol. 2009; 30(12): 1203–10.

3. Lipsky B.A., Moran G.J., Napolitano L.M. et al. A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes. BMC Infect. Dis. 2012; (12): 227 (Р. 1–12) http://www.biomedcentral.com/1471-2334/12/227.

4. Stevens D.L., Bisno A.L., Chambers H.F. et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin. Infect. Dis. 2014; 59: 147–59.

5. May A.K. Skin and soft tissue infections. Surg. Clin. North. Am. 2009; 89(2): 403–20.

6. Kozlov R.S., Krechikova O.I., Ivanchik N.V. et al. Etiology of Nosocomial Bacterial Infections in Russia. Rosnet Study Group. Proceedings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. 25–28 October, 2008. Washington, DC, USA.; 572, abst. K-4108

7. Dryden M.S. Complicated skin and soft tissue infection. J. Antimicrob. Chemother. 2010; 65(Suppl. 3): 11135–44.

8. Di Nubile M.J., Lipsky B.A. Complicated infections of skin and skin structures: when the infection is more than skin deep. J. Antimicrob. Chemother. 2004; 53(Supрl.2): 1137–50.

9. Ратникова Л.И., Шип С.А. Современные клинико-лабораторные и гендерные особенности рожи. Эпидемиол. и инфекц. бол. 2013; (3): 19–21.

10. Фокина Е.Г., Рослый И.М., Потекаева С.А. Лабораторная оценка рожистого воспаления. Эпидемиол. и инфекц. болезни. Актуал. вопр. 2014; (1): 28–32.

11. Larru B., Gerber J.S. Cutaneous bacterial infections caused by Staphylococcus aureus and Streptococcus pyogenes in infants and children. Pediatr. Clin. N. Am. 2014; 61: 457–78.

12. Gunderson C.G., Martinello R.A. A systematic review of bacteriemias in cellulitis and erysipeals. J. Infect. 2012; 64: 148–55.

13. Eriksson B., Jorup-Ronstrom C., Karkkonen K., Sjoblom A.C., Holm S.E. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin. Infect. Dis. 1996; 23(5): 1091–8.

14. Троицкий В.И., Еровиченков А.А., Потекаева С.А., Свистунова Т.С., Белая О.Ф., Волчкова Е.В. Разнообразие выявляемых возбудителей у больных рожей. Эпидемиол. инфекц. бол. 2015; (2): 34–7.

15. Cosgrove S., Sakoulas G., Perencevich E. et al. Comparison of mortality associated with methicillin-resistantand methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 2003; 36: 53–9.

16. Ramakrishnan K., Salinas R., Higuita NIA. Skin and soft tissue infections. Am. Family Phys. 2015; 92(6): 474–83.

17. Дибиров М.Д., Гаджимуратов Р.У., Лебедев В.В., Терещенко С.А. Выбор антибактериальной терапии при лечении гнойных осложнений синдрома диабетической стопы. Инфекции в хирургии 2009; 12(11): 113–7.

18. Белобородов В.Б. Современные принципы применения левофлоксацина в лечении инфекций кожи и мягких тканей. Consilium medicum 2009; (1): 38–42.

19. Bowler P. Duerden B. Armstrong D. Wound microbiology and associated approaches to wound management. Clin. Microbiol Rev. 2001; 14 (2): 244–69.

20. Еровиченков А.А., Домонова Э.А., Потекаева С.А., Свистунова Т.С., Матосова С.В., Шипулина О.Ю., Малолетнева Н.В., Шипулин Г.А., Пак С.Г. Современные молекулярно-биологические методы в изучении этиологии буллезно-геморрагической формы рожи нижних конечностей. Инфекционные болезни 2016; 14(2): 6–12.

21. Bally M., Dendukuri N., Sinclair A., Ahern S.P., Poisson M., Brophy J. A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection. Int. J. Antimicrob. Agents 2012; 40(6): 479–95.

22. Logman J.F., Stephens J., Heeg B. et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr. Med. Res. Opin. 2010; 26(7): 1565–78.

23. Bounthavong M., Hsu D.I. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr. Med. Res. Opin. 2010; 26(2): 407–21.

24. Beibei L., Yun C., Mengli C., Nan B., Xuhong Y., Rui W. Linezolid versus vancomycin for the treatment of gram- positive bacterial infections: meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents 2010; 35(1): 3–12.

25. Lin D.F., Zhang Y.Y., Wu J.F. et al. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int. J. Antimicrob. Agents 2008; 32(3): 241–9.

26. Kohno S., Yamaguchi K., Aikawa N. et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J. Antimicrob. Chemother. 2007; 60(6): 1361–9.

27. Food and Drug Administration. Guidance for Industry, Uncomplicated and Complicated Skin and Skin Structure Infections – Developing Antimicrobial Drugs for Treatment. 1998. https://www.fda.gov/ohrms/dockets/98fr/2566dft.pdf

28. Food and Drug Administration. Guidance for Industry Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. 2013. http://www.fda.gov/downloads/Drugs/.../Guidances/.

29. Picazo J. Betriu C., Rodrhuez-Avial I. et al. Vigilancia de resistencias a los antimicrobianos: Estudio VIRA. Enferm. Infect. Microbiol. Clin. 2002; 20: 503–10.

30. Rybak J., Roberts K. Tedizolid phosphate: a next-generation oxazolidinone. Infect. Dis. Ther. 2015; (4): 1–14.

31. Amin A., Cerceo A., Deitelzweig B. et al Hospitalist perspective on the treatment of skin and soft tissue infections. Mayo Clin. Proc. 2014; 1–16.

32. Prokocimer P., De Anda C., Fang E. et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013; 309: 559–69.

33. Moran G.J., Fang E., Corey G.R. et al. Tedizolid for 6 days vs linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect. Dis. 2014; 14(8): 696–705.

34. Shorr A., Lodise T., Corey G.R. et al. Analysis of the phase 3 ESTABLISH trials: tedizolid versus linezolid in acute bacterial skin and skin structure infection. Antimicrob. Agents Chemother. 2015; 59(2): 864–71. DOI: 10.1128/AAC.03688-14.

35. Im W.B., Choi S.H., Park J.Y., Choi S.H., Finn J., Yoon S.H. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur. J. Medicine Chem. 2011; 46(4): 1027–39.

36. Ye Hui, Lü Xiaoju. Tedizolid for treatment of acute bacterial skin and skin structure infections. Expert Review of Anti-infective Therapy 2015; 13(9): 1051–60.

37. Sahre M., Sabarinath S., Grant M. et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int. J. Antimicrob. Agents 2012; 40(1): 51–4.

38. Lemaire S., van Bambeke F., Appelbaum P.C., Tulkens P.M. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J. Antimicrob. Chemother. 2009; 64(5): 1035–43.

39. Drusano G.L., Liu W., Kulawy R., Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob. Agents Chemother. 2011; 55(11): 5300–5.

40. Housman S.T., Pope J.S., Russomanno J. et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob. Agents Chemother. 2012; 56(5): 2627–34.

41. Jones R.N., Moet G.J., Sader H.S. et al. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J. Antimicrob. Chemother. 2009; 63(4): 716–20.

42. Flanagan S., McKee E.E., Das D., Tulkens P.M., Hosako H., Fiedler-Kelly J., Passarell J., Radovsky A., Prokocimer P. Evaluation of the Potential of Tedizolid and Linezolid to Affect Mitochondrial Function Using Nonclinical and Pharmacokinetic Assessments. Antimicrob Agents Chemother. 2015; 59(1): 178–85.

43. Locke J.B., Hilgers M., Shaw K.J. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob. Agents Chemother. 2009; 53(12): 5265–74.

44. Locke J.B., Morales G., Hilgers M. et al. Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3. Antimicrob. Agents Chemother. 2010: 54(12): 5352–5.

45. Flanagan S.D., Bien P.A., Muñoz K.A. et al. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy 2014; 34(3):240–50.

46. Flanagan S., Fang E., Muñoz KA. et al. Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid. Pharmacotherapy 2014; 34: 891–900.

47. Prokocimer P., Bien P., Munoz K.A. et al. Hematological Effects of TR-701, Linezolid and Placebo Administered for 21 Days in Healthy Subjects. Presented at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. 25–28 October, 2008. Washington, DC, USA. Poster F1-2069a.

48. Flanagan S., Passarell J., Lu Q. et al. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob. Agents Chemother. 2014; 58(11): 6462–70.

49. Flanagan S., Bartizal K., Minassian S.L. et al. In vitro, in vivo and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob. Agents Chemother. 2013; 57(7): 3060–6.

50. Ong V., Flanagan S., Fang E. et al. Absorption, distribution, metabolism and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab. Dispos. 2014; 42(8): 1275–84

51. Fang E. Characterization of neurologic and ophthalmologic safety of oral administration of tedizolid for up to 21 days in healthy volunteers. American Journal of Therapeutics 2017; 24 (2): 227– 33.